Results for tag: "Cell Free Fetal DNA Testing"

Within the field of genomics, Cell-Free Fetal DNA (cffDNA) testing represents a major advancement in non-invasive prenatal diagnostics. This type of testing analyzes fetal DNA that circulates freely in the maternal bloodstream to screen for potential genetic abnormalities, such as chromosomal aneuploidies like Down syndrome, Edwards syndrome, and Patau syndrome, without posing a risk to the fetus. As a subset of the broader prenatal testing market, cffDNA tests leverage next-generation sequencing and advanced bioinformatics to provide expectant parents and healthcare providers with early insights into fetal health. The availability of such non-invasive methods has transformed prenatal care, allowing for earlier and safer detection of genetic conditions compared to traditional invasive methods like amniocentesis or chorionic villus sampling, which carry risks for both mother and child. Several companies are at the forefront of the cffDNA testing market, contributing to its growth and innovation. Prominent players in this field include Illumina, Inc., through their subsidiary Verinata Health, which offers the Verifi prenatal test, as well as Sequenom Laboratories with their MaterniT test. Other key companies include Natera, Inc., providing the Panorama test, and Ariosa Diagnostics, which developed the Harmony Prenatal Test. These organizations, among others, continue to refine their technologies and expand the scope of detectable conditions, thus enhancing the selection of non-invasive prenatal testing options for expecting families. Show Less Read more